These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17932596)

  • 1. Should fluoroquinolones be first-line antibiotics in the treatment of community-acquired pneumonia in areas with high incidence of tuberculosis?
    Hsueh PR
    J Microbiol Immunol Infect; 2007 Oct; 40(5):386-7. PubMed ID: 17932596
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity.
    Singh A
    Clin Infect Dis; 2007 Jul; 45(1):133; author reply 134-5. PubMed ID: 17554716
    [No Abstract]   [Full Text] [Related]  

  • 3. Community-acquired pneumonia.
    Luh JY; Karnath BM
    N Engl J Med; 2003 Apr; 348(14):1408-9; author reply 1408-9. PubMed ID: 12672875
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective.
    Low DE
    Clin Infect Dis; 2009 May; 48(10):1361-3. PubMed ID: 19348596
    [No Abstract]   [Full Text] [Related]  

  • 5. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.
    Grossman RF; Hsueh PR; Gillespie SH; Blasi F
    Int J Infect Dis; 2014 Jan; 18():14-21. PubMed ID: 24211230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches to treatment of community-acquired pneumonia in the emergency department and the appropriate role of fluoroquinolones.
    Schriger DL; Hoffman JR; Cooper RJ; Gupta M
    J Emerg Med; 2007 Aug; 33(2):197; discussion 197. PubMed ID: 17692777
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monotherapy or combination therapy for hospitalized patients with community-acquired pneumonia: not yet the end of the story?
    Laterre PF
    Clin Infect Dis; 2008 May; 46(10):1510-2. PubMed ID: 18419483
    [No Abstract]   [Full Text] [Related]  

  • 9. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis.
    Long R; Chong H; Hoeppner V; Shanmuganathan H; Kowalewska-Grochowska K; Shandro C; Manfreda J; Senthilselvan A; Elzainy A; Marrie T
    Clin Infect Dis; 2009 May; 48(10):1354-60. PubMed ID: 19348594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.
    Nakamura S; Yanagihara K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Senjyu H; Saito A; Kohno S
    J Infect; 2009 Sep; 59(3):222-4. PubMed ID: 19592113
    [No Abstract]   [Full Text] [Related]  

  • 11. Initial evaluation and management of the patient with suspected pneumonia.
    Hackman JL
    Mo Med; 2008; 105(6):518-22. PubMed ID: 19052015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumonia, tuberculosis, and urinary tract infections in pregnancy.
    Riley LE
    Curr Clin Top Infect Dis; 1999; 19():181-97. PubMed ID: 10472486
    [No Abstract]   [Full Text] [Related]  

  • 13. Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: an instructive case.
    Grupper M; Potasman I
    Am J Med Sci; 2008 Feb; 335(2):141-4. PubMed ID: 18277123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do fluoroquinolones actually increase mortality in community-acquired pneumonia?
    Agarwal R
    Crit Care; 2006 Feb; 10(1):403; author reply 403. PubMed ID: 16469131
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimizing therapy for community-acquired pneumonia with the goal of rapid resolution of illness.
    File TM; Tan JS
    Clin Infect Dis; 2005 Dec; 41(12):1706-8. PubMed ID: 16288391
    [No Abstract]   [Full Text] [Related]  

  • 16. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli.
    Gagliotti C; Buttazzi R; Sforza S; Moro ML;
    J Infect; 2008 Sep; 57(3):179-84. PubMed ID: 18707763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemifloxacin (factive).
    Med Lett Drugs Ther; 2004 Sep; 46(1192):78-9. PubMed ID: 15452464
    [No Abstract]   [Full Text] [Related]  

  • 18. Does radiographic evidence of prior pulmonary tubercular infection influence the choice of empiric antibiotics for community-acquired pneumonia in a tuberculosis-endemic area?
    Jeng YY; Lin YT; Huang LJ; Chen TL; Wang FD; Fung CP; Liu CY
    J Microbiol Immunol Infect; 2010 Oct; 43(5):386-94. PubMed ID: 21075705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Short course antibiotherapies in community-acquired pneumonia].
    Bulbul Y; Ozlu T
    Tuberk Toraks; 2008; 56(3):344-52. PubMed ID: 18932039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and treatment recommendations for community acquired pneumonia.
    Gifford DS
    Med Health R I; 2002 Jan; 85(1):30-1. PubMed ID: 11824153
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.